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DOI 10.1016/j.chembiol.2012.04.005Chronic hepatitis C infections have been
difficult to clear from the body because
the virus has found so many ways to
coexist with humans. The genome of
the hepatitis C virus (HCV) contains
features that allow for quick mutations
that scoot around medications. Easy
mutations also make vaccine develop-
ment and drug design especially prob-
lematic. For the past 20 years or so, the
six main HCV genotypes have been
treated with the same drug regimen,
but genotype I, the most common in
Europe and North America, has proven
the most problematic to treat. What’s
more, the health care community in
the United States can only estimate the
total number of people with chronic
HCV infections.Fortunately, the HCV therapy pipeline is transporting targeted
therapies for genotype I to the clinic.Until recently, the standard of care for
HCV has been pegylated interferon
(peginterferon) and ribavirin (Virazole),
which help dampen the immune re-
sponse in a general way. Although neither
drug specifically targets HCV, around
80% of people with most genotypes re-
spond well enough to achieve what phy-
sicians call a sustained virological re-
sponse, meaning that the virus can’t be
detected in the bloodstream for 6 months
or longer. Such patients are considered
cured.
Unfortunately, response rates to pegin-
terferon and ribavirin for those infected
with genotype I are much lower—about
40%–50%. For those infected patients
who didn’t respond at all, there was noth-
ing physicians could offer, at least from
a treatment standpoint.
Fortunately, the HCV therapy pipeline
is transporting targeted therapies for
genotype I to the clinic. Additional tar-
geted therapies are in various stages
of clinical trials. These therapies have
already boosted the sustained virological
response for genotype I.In 2011, the Food and Drug Adminis-
tration approved two new treatments.
Both are protease inhibitors that target
molecular features in genotype 1. Telap-
revir (ICIVEK) is manufactured by Vertex
Pharmaceuticals, Incorporated, in Cam-
bridge, Massachussets, and Boceprevir
(VICTRELIS), from Merck of Whitehouse
Station, New Jersey. When the new ther-
apies are given in combination with pegin-
terferon and ribavirin, the cure rates reach
70%–80% for genotype I.
‘‘These drugs certainly mean an
improvement in outcome and potentially
shorter therapy for patients with geno-
type 1. They can also be used for patients
who failed previous therapy. So overall
they are an important step forward,
although there will still be a substantialminority (perhaps a quarter) of patients
who go through the therapy and still fail
to clear the virus,’’ Paul Klenerman, M.D.,
Ph.D., a clinician and immunologist at
University of Oxford, England, wrote in
an email.
Silent Disease, Costly Therapy
The peak years for HCV infections
were the 1960s and 1970s. At the time,
doctors knew the infections were a form
of hepatitis but the virus hadn’t been
identified; they just knew that it wasn’t
hepatitis A or B, so HCV was called,
‘‘non-A’’ or ‘‘non-B.’’ In 1989, with the dis-
covery of the virus, came the serologic
means to establish a diagnosis.
By the late 1980s, the virus was treated
with the immune glycoprotein interferon.
Once HCV was identified as a flavivirus, a
family of RNA viruses that includes West
Nile, the antiviral ribavirin was added to
the treatment regimen because it worked
against flaviviruses. Shortly after, inter-
feronwas chemically alteredwith polyeth-
ylene glycol to last longer in the blood-
stream. Injections of peginterferon couldChemistry & Biology 19, April 20, 2012be given weekly rather than three times
a week.
Worldwide, more than 170 million
people are estimated to be chronically
infected with HCV. In the United States,
around 700,000 cases are known; an esti-
mated 3 million cases are suspected.
Pinning down that number is difficult
because HCV attacks the liver slowly
and silently for two to three decades.
Those infected don’t know they carry
a deadly virus until the liver is nearly
destroyed. Often, the only symptom is
fatigue—a warning easily attributed to
other conditions.
The potentially millions of people who
unknowingly carrying the virus makes
hepatitis C ‘‘a gigantic health issue
because hepatitis C is responsible for
most liver transplants and for most cases
of liver cancer,’’ says Mauricio Lisker-
Melman M.D., a gastroenterologist at
Washington University School of Medi-
cine in St. Louis, Missouri.
HCV has a high tendency to become
chronic if the infection persists beyond
6 months. Because the virus is indolent,
once a chronic infection establishes itself,
HCV slowly damages the liver decade
after decade without stopping, unless
a blood test detects the virus and a treat-
ment regimen begins. If undetected, the
path to liver destruction can take 20 to
30 years, or more.
At first, HCV triggers inflammation, then
fibrosis, a scarring and thickening of the
tissue that slowly spreads throughout
the liver. Unchecked fibrosis leads to
cirrhosis. By the time cirrhosis occurs,
most of the healthy liver tissue has been
replaced with scarring. Patients with
cirrhosis go on to develop liver cancer at
rate of 3%–5% per year.
HCV doesn’t incorporate its genetic
material into the host genome (unlike
HIV and hepatitis B), so the aim of treat-
ment is eradication of the virus. Once
the virus is cleared, it’s gone, says Adrian
Di Bisceglie, M.D., a gastroenterologist
at Saint Louis University in St. Louis,
Missouri.ª2012 Elsevier Ltd All rights reserved 433
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treatment in addition to plenty of money.
Treatment lasts for about 45 weeks and
costs around $60,000 per year. Side
effects can include decreased ability to
concentrate, depression, suppression of
bone marrow, and flu-like symptoms.
Patients are then monitored closely by
a physician for five years.
Once the virus is gone, the fibrosis and
even cirrhosis can start reversing itself.
‘‘That was a novelty here, because we
used to think that the fibrosis and scarring
didn’t go away, but we’ve seen that it can
decrease substantially and even go away
after a few years,’’ says Di Bisceglie.
Treating Nonresponders
Helping those who have never responded
to standard therapy has been difficult for
physicians. Telaprevir and boceprevir are
providing such patients with another
chance. Such patients are good candi-
dates fornew therapies, but their response
to the new drugs isn’t as strong as those
who have never received any treatment,
says Darius Moradpour, M.D., a hepa-
tologist at the University of Lausanne,
Switzerland. New drugs in clinical trials
may provide new options.
Anna Lok, M.D., a gastroenterologist
at the University of Michigan Health
System in Ann Arbor, led a preliminary
study that tested the safety and efficacy
of two new antivirals on patients who
had received previous treatment with
peginterferon and ribavirin but had not
responded. This exploratory study in-
cluded 21 men and women ages 18–70
years old with chronic HCV genotype I.
The patients had no cirrhosis. Patients
were randomly assigned to receive either
daclatasvir, which keeps the virus from
replicating, or asunaprevir, a protease
inhibitor; both are manufactured by Bris-
tol-Meyers Squibb, based in Hopewell,
New Jersey. The experimental drugs
were given in combination either with or
without peginterferon and ribavirin, (Lok
et al., 2012).
The aimwas to figure out whether treat-
ment for 24 weeks would eliminate most434 Chemistry & Biology 19, April 20, 2012 ªtraces of the virus from the bloodstream.
Although the virus broke through in
some patients and resistance to the anti-
virals occurred in 11 patients, 36% re-
ceiving the two oral antivirals without
peginterferon and ribavirin achieved a
sustained virological response 24 weeks
after the therapy stopped, which Lok
says provides proof of concept that it is
possible to eliminate hepatitis C virus
without peginterferon and ribavirin. Lok
emphasizes that the study showed that
the four drug regimen with two new oral
antivirals plus peginterferon and ribavirin
achieved sustained virological response
in 9 of 10 patients that are very difficult
to treat.
‘‘For 10 years, we had only peginter-
feron and ribavirin. Retreating patients
who had failed to respond with the same
treatment is, as expected, futile in most
cases. Now that we have new drugs,
it opens up all sorts of possibilities,’’
says Lok.
Identifying Those Infected
With new treatments in hand and the
specter of millions silently infected, the
health care community is trying to identify
as many people with HCV as possible.
That’s not an easy task. The Centers for
Disease Control and Prevention has a
long list of screening recommendations,
including those in contact with blood or
blood products, those who have had
blood transfusions or a transplant prior
to 1990, and those who’ve had multiple
sexual partners, used intravenous drugs,
or have tattoos.
A specific blood test for HCV exists but
doctors need amedical reason for the test
to be administered. That’s not as straight-
forward as it could be, as screening
recommendations rely on physicians to
ask sensitive questions about drug use
and sexuality that patients may be reluc-
tant to answer or doctors may be reluc-
tant to ask. Also, tests for liver enzymes
may not be included in routine physicals.
If they are, says Lisker-Melman, a slight
increase in liver enzymes may or may
not mean the presence of HCV.2012 Elsevier Ltd All rights reserved‘‘When you combine both the ability of
doctors to ask those questions and the
reluctance of patients to answer them
you recognize that the situation is less
than ideal,’’ says Lisker-Melman. ‘‘But if
we don’t recognize this disease, and we
don’t start treating patients early on in
their natural history, we will see more
patients affected in the later stages with
little possibility of a cure.’’
Currently, the CDC is refining recom-
mendations based on birth cohort screen-
ing, rather than relying on doctors to ask
questions that patients may not answer
in an honest fashion. The recommenda-
tions are expected to advise testing baby
boomers, those born between 1945 and
1965.
If baby boomers are screened and
such screening dramatically increases
the numbers of those with HCV, Lisker-
Melman says that the newly diagnosed
patients would need to go on the new
treatment regime, which would save lives.
However, such treatment costs $60,000
per year, which would be difficult to afford
for people without health insurance or
a good health support system.
‘‘A lot of patients with HCV in the west
are in marginalized groups, especially
intravenous drug users, who may not
have optimal access to health care, or
other medical and social issues which
mean they cannot access these complex
treatments. In other countries, including
Egypt, where there is a huge burden
of disease, much of the disease is non-
genotype 1, which means the new drugs
will not be useful. But also importantly,
the cost of the treatment and the com-
plexity of delivery means it is not really
yet affordable in many countries,’’ Klener-
man wrote in an email.
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